Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Minerva Neurosciences, Inc - Common Stock (NQ:NERV)

4.585 -0.115 (-2.45%)
Streaming Delayed Price Updated: 1:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Minerva Neurosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst ↗
Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Minerva Stock Rises After Securing $200M for Schizophrenia Drug Trial ↗
Minerva Neurosciences Inc (NASDAQ:NERV) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia. 
Via Benzinga
News headline image
These stocks are the most active in today's session ↗
Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
US Stocks Mixed; Coca-Cola Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Tuesday. ↗
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Unusual volume stocks are being observed in Wednesday's session. ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
Top movers in Wednesday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
NERV Stock Earnings: Minerva Neurosciences Misses EPS for Q2 2024 ↗
NERV stock results show that Minerva Neurosciences missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
NERV Stock Earnings: Minerva Neurosciences Beats EPS for Q1 2024 ↗
NERV stock results show that Minerva Neurosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings ↗
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41.... 
Via Benzinga
Topics Stocks
News headline image
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
News headline image
Regulatory Setback For Minerva Neurosciences' Schizophrenia Treatment Candidate, FDA Asks For More Data ↗
Minerva Neurosciences faces FDA challenges for roluperidone in schizophrenia treatment. Understand the clinical deficiencies and potential paths forward. Cash position at December 31, 2023, around... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.